On November 4, 2016 Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; "Sumitomo Dainippon Pharma") reported that clinical data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in San Diego from December 3 to 6, 2016 (Press release, Dainippon Sumitomo Pharma, NOV 4, 2016, View Source [SID1234516253]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Planned poster sessions include:
1. Abstract #4335, [637. Myelodysplastic Syndromes―Clinical Studies: Poster III]
Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)
Presenter: S. Miyakoshi (Department of Hematology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan)
Monday, December 5 from 6:00 p.m. – 8:00 p.m. (local time), Hall GH
The abstract is now available on the official website of ASH (Free ASH Whitepaper) (URL: View Source)
Highlights of the abstract】
In phase 1 portion, azacitidine (the first-line treatment option) failure higher-risk (7 patients) and transfusion-dependent lower-risk (5 patients) MDS patients (total 12 patients) were enrolled in 3.5 or 10.5 mg/body cohorts. Safety and tolerability were evaluated, and delayed type hypersensitivity (DTH), WT1-specific CTL induction and expression of WT1 mRNA in peripheral blood and bone marrow cells were also examined.

DSP-7888 was well-tolerated in MDS patients and dose-dependent toxicity was not observed except for ISR, although ISR was observed in all patients.

Disease control rate (PR+SD) was observed in 66.6 % and CTL induction, one of the secondary clinical activities, was observed in 50% of the 12 evaluable patients.

2. Abstract #4715, [802. Chemical Biology and Experimental Therapeutics: Poster III]
DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1
Note:This data is non-clinical evaluation. 2
Presenter: M. Goto (DSP Cancer Institute, Sumitomo Dainippon Pharma Co., Ltd., Japan) Monday, December 5 from 6:00 p.m. – 8:00 p.m. (local time), Hall GH
The abstract is now available on the official website of ASH (Free ASH Whitepaper) (URL: View Source)